NRx Pharmaceuticals (NASDAQ:NRXP) Announces Earnings Results

NRx Pharmaceuticals (NASDAQ:NRXP) announced its earnings results on Friday. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.07), Zacks reports. The firm had revenue of $1.10 million for the quarter, compared to the consensus estimate of $1.33 million.

NRx Pharmaceuticals Stock Down 2.1%

NASDAQ:NRXP opened at $3.27 on Friday. The stock’s 50-day simple moving average is $3.80 and its 200 day simple moving average is $2.95. NRx Pharmaceuticals has a twelve month low of $1.62 and a twelve month high of $5.05. The firm has a market capitalization of $118.47 million, a PE ratio of -5.95 and a beta of 2.18.

Institutional Investors Weigh In On NRx Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. Anson Funds Management LP grew its holdings in shares of NRx Pharmaceuticals by 50.3% during the fourth quarter. Anson Funds Management LP now owns 3,043,957 shares of the company’s stock worth $8,249,000 after purchasing an additional 1,018,853 shares during the last quarter. Vanguard Group Inc. increased its position in shares of NRx Pharmaceuticals by 18.3% during the third quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock worth $1,765,000 after buying an additional 82,781 shares during the period. Commonwealth Equity Services LLC bought a new position in shares of NRx Pharmaceuticals in the 4th quarter worth about $994,000. Geode Capital Management LLC increased its holdings in NRx Pharmaceuticals by 17.8% in the fourth quarter. Geode Capital Management LLC now owns 218,866 shares of the company’s stock worth $593,000 after purchasing an additional 33,004 shares in the last quarter. Finally, State Street Corp increased its stake in shares of NRx Pharmaceuticals by 14.0% in the 4th quarter. State Street Corp now owns 86,984 shares of the company’s stock valued at $236,000 after acquiring an additional 10,700 shares in the last quarter. Institutional investors own 4.27% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on NRXP. HC Wainwright restated a “buy” rating on shares of NRx Pharmaceuticals in a research report on Monday, August 10th. Wall Street Zen downgraded shares of NRx Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday. Weiss Ratings reiterated a “sell (d-)” rating on shares of NRx Pharmaceuticals in a report on Wednesday, August 5th. BTIG Research lowered their price target on shares of NRx Pharmaceuticals to $10.00 and set a “buy” rating on the stock in a research note on Friday, August 7th. Finally, D. Boral Capital reiterated a “buy” rating and set a $34.00 price objective on shares of NRx Pharmaceuticals in a research note on Tuesday, May 5th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $34.50.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.